Pharmaceutical Business Review
November 23, 2011
Prana Biotechnology has secured approval from the Austin Health Research
Ethics Committee to commence a 12 month Phase II Imaging trial evaluating its
PBT2 drug for Alzheimer’s disease.
The double blind, placebo controlled trial will enroll 40 patients with
prodromal or mild Alzheimer’s disease to measure physical changes in the brains
of patients treated with PBT2 for 12 months and evaluate the effects of PBT2 on
patients’ cognition reported in the earlier trial.
The 12-month trial is based on the success of an earlier Phase IIa clinical
trial of PBT2 that showed an improvement in cognition.
Prana executive chairman Geoffrey Kempler said the earlier 12-week trial
reported an improvement in cognition and change in Abeta levels in spinal
”We believe that in this 12 month trial PBT2 will establish its credentials
as a safe and effective treatment for Alzheimer’s Disease,” Kempler added.